Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

Area of Science:

• Mitochondrial biology
• Proteolysis
• Cancer cell biology

Background:

• Mitochondrial caseinolytic protease P (ClpP) is crucial for protein quality control via degrading misfolded proteins.
• Cancer cells exhibit altered metabolic dependencies, making them potential targets for specific interventions.

Purpose of the Study:

• To investigate the therapeutic potential of hyperactivating mitochondrial ClpP in cancer treatment.
• To identify compounds that can selectively activate ClpP and induce cancer cell death.

Main Methods:

• Genetic and chemical approaches to modulate ClpP activity.
• Biochemical assays and crystallography to study compound-protein interactions.
• Assessment of cancer cell viability and mitochondrial function.

Main Results:

• Hyperactivation of ClpP selectively eliminates cancer cells, irrespective of p53 status.
• Activated ClpP degrades respiratory chain proteins, disrupting mitochondrial structure and function in cancer cells.
• Non-malignant cells remain unaffected by ClpP hyperactivation.
• Imipridones were identified as potent, non-covalent ClpP activators that induce proteolysis through structural changes.

Conclusions:

• Targeting mitochondrial proteolysis via ClpP activation represents a promising strategy for cancer therapy.
• Imipridones demonstrate potential as cancer therapeutics by selectively inducing cancer cell lethality.
• The findings support a generalizable concept of targeting mitochondrial protein degradation pathways for cancer treatment.